Substantial evidence of effect

Journal of Biopharmaceutical Statistics

Volumn 12, Issue 1, 2002, Pages 53-77

  Gould, A Lawrence ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Equivalence; Multiplicity; Noninferiority; Trial design

Indexed keywords

CARVEDILOL; CARBAZOLE DERIVATIVE; FIBRINOLYTIC AGENT; PROPANOLAMINE DERIVATIVE;

ARTICLE; ASSAY; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; MEDICAL ETHICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK BENEFIT ANALYSIS; VALIDATION PROCESS; CLINICAL TRIAL; DRUG SCREENING; EPIDEMIOLOGY; HUMAN; METHODOLOGY; UNITED STATES;

CARBAZOLES; CLINICAL TRIALS; DRUG EVALUATION; EPIDEMIOLOGIC RESEARCH DESIGN; FIBRINOLYTIC AGENTS; GUIDELINES; HUMAN; PROPANOLAMINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; HUMANS;

EID: 0035997112     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-120005740     Document Type: Article

References (63)

1. Goodman p-values, and evidence
2. The behavior of the p-value when the alternative hypothesis is true
3. The design of replicated studies
4. Statistical issues for HIV surrogate endpoints: Point/counterpoint. An NIAID Workshop
5. Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints
6. Criteria for the validation of surrogate endpoints in randomized experiments
7. Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
8. Meta-analysis for the evaluation of potential surrogate markers
9. Trial design based on surrogate end points-application to comparison of different breast screening frequencies
10. Properties of a nonparametric test for early comparison of treatments in clinical trials in the presence of surrogate endpoints
11. The relationship between study design, results, and reporting of randomized clinical trials of HIV infection
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
13. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
14. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
15. The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure
16. Surrogate end points in clinical trials: Are we being misled?
17. Equipoise and the ethics of clinical research
18. Community equipoise and the architecture of clinical research
19. The use of equipoise in clinical trials
20. Difficulties in evaluating positive control trials
21. Inherent difficulties with active control equivalence studies
22. When are clinical trials of a given agent vs placebo no longer appropriate or feasible?
23. Practical issues in equivalence trials
24. Some issues in the design and analysis of equivalence trials
25. Placebo-controlled trials and active-control trials in the evaluation of new treatments 1: Ethical and scientific issues
26. Placebo-controlled trials and active-control trials in the evaluation of new treatments 2: Practical issues and specific cases
27. The need to revise the declaration of Helsinki
28. FDA, The use of placebos in clinical trials and the ethics of the use of placebos
29. Ethical issues in the design and conduct of clinical trials in developing countries
30. Special study designs: Early escape, enrichment, studies in non-responders
31. A three-stage clinical trial design for rare disorders
32. Applications of interval inference
33. Another view of active-controlled trials
34. Recommendations guiding physicians in biomedical research involving human subjects
35. Proposed revisions to the declaration of Helsinki - Will they weaken the ethical principles underlying human research?
36. Declaration of helsinki should be strengthened
37. Declaration of helsinki should be strengthened
38. A perspective on the regulation of the evaluation of new antithrombotic drugs
39. The role of meta-analysis in the regulatory process for foods, drugs, and devices
40. International Joint Efficacy Comparison of Thrombolytics; Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence
41. Cavedilol and the food and drug administration approval process: An introduction
42. Carvedilol and the Food and Drug Administration (FDA) Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing
43. End-point interpretation in clinical trials: The case for discipline
44. An improved bonferroni procedure for multiple tests of significance
45. Controlling the false discovery rate: A practical and powerful approach to multiple testing
46. Treatment with Bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
47. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
48. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
49. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
50. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
51. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
52. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
53. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
54. Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction
55. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty